AU2001253886A1 - Methylxanthines in the diagnosis and treatment of autistic disorder - Google Patents
Methylxanthines in the diagnosis and treatment of autistic disorderInfo
- Publication number
- AU2001253886A1 AU2001253886A1 AU2001253886A AU5388601A AU2001253886A1 AU 2001253886 A1 AU2001253886 A1 AU 2001253886A1 AU 2001253886 A AU2001253886 A AU 2001253886A AU 5388601 A AU5388601 A AU 5388601A AU 2001253886 A1 AU2001253886 A1 AU 2001253886A1
- Authority
- AU
- Australia
- Prior art keywords
- methylxanthines
- diagnosis
- treatment
- autistic disorder
- autistic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19642300P | 2000-04-12 | 2000-04-12 | |
US60196423 | 2000-04-12 | ||
PCT/US2001/040505 WO2001079837A1 (en) | 2000-04-12 | 2001-04-12 | Methylxanthines in the diagnosis and treatment of autistic disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001253886A1 true AU2001253886A1 (en) | 2001-10-30 |
Family
ID=22725358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001253886A Abandoned AU2001253886A1 (en) | 2000-04-12 | 2001-04-12 | Methylxanthines in the diagnosis and treatment of autistic disorder |
Country Status (3)
Country | Link |
---|---|
US (1) | US6365593B2 (en) |
AU (1) | AU2001253886A1 (en) |
WO (1) | WO2001079837A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7897141B2 (en) * | 2002-04-01 | 2011-03-01 | Drexel University | Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof |
US7947285B2 (en) * | 2003-12-12 | 2011-05-24 | Fein Seymour H | Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis |
US7381698B2 (en) * | 2003-12-12 | 2008-06-03 | Chirhoclin, Inc. | Methods for treatment of acute pancreatitis |
US10060932B2 (en) | 2013-07-09 | 2018-08-28 | Stemina Biomarker Discovery, Inc. | Biomarkers of autism spectrum disorder |
US9176113B1 (en) * | 2014-04-11 | 2015-11-03 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
US20150294081A1 (en) | 2014-04-11 | 2015-10-15 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
US10525020B2 (en) | 2015-02-11 | 2020-01-07 | Laboratory Corporation Of America Holdings | Metabolic markers of attention deficit hyperactivity disorder |
WO2017210540A1 (en) | 2016-06-03 | 2017-12-07 | The Trustees Of Columbia University In The City Of New York | Methods of treating prader-willi syndrome |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61277618A (en) * | 1985-06-04 | 1986-12-08 | Suntory Ltd | Remedy for autism |
US5008251A (en) * | 1986-03-27 | 1991-04-16 | The Regents Of The University Of California | Method of treating autism |
FR2665636B1 (en) * | 1990-08-10 | 1994-10-07 | Adir | USE OF A TRIMETHYL-1,3,7 XANTHINE DERIVATIVE FOR THE TREATMENT OF MEMORY DISORDERS, INTELLECTUAL DISORDERS OF SENESCENCE AND ALZHEIMER'S DISEASE. |
FR2692784B1 (en) | 1992-06-24 | 1995-06-30 | Pf Medicament | USE OF GUANOSINE, ITS PRECURSORS AND DERIVATIVES FOR THE MANUFACTURE OF MEDICINES FOR TREATING CEREBRAL FUNCTIONAL DEFICITS. |
US5686311A (en) | 1995-06-23 | 1997-11-11 | The Children's Mercy Hospital | Diagnosis of autism and treatment therefor |
JP2002501616A (en) * | 1997-05-19 | 2002-01-15 | リプリゲン コーポレーション | Methods to assist in differential diagnosis and treatment of autistic syndrome |
-
2001
- 2001-04-12 WO PCT/US2001/040505 patent/WO2001079837A1/en active Application Filing
- 2001-04-12 AU AU2001253886A patent/AU2001253886A1/en not_active Abandoned
- 2001-04-12 US US09/834,169 patent/US6365593B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20020019407A1 (en) | 2002-02-14 |
US6365593B2 (en) | 2002-04-02 |
WO2001079837A1 (en) | 2001-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001293553A1 (en) | Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment | |
AU2001236798A1 (en) | Optically-active nanoparticles for use in therapeutic and diagnostic methods | |
HUP0203367A3 (en) | Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes | |
IL138732A0 (en) | The use of polyamines in the treatment of dermatological symptoms | |
IL187512A0 (en) | Use of (s,s)-reboxetine in the treatment of pain conditions and incontinence | |
IL205242A0 (en) | Substituted oxazolidinones and their use in the field of blood coagulation | |
AU3021001A (en) | Thiazolidine carboxylic acid derivatives and their use in the treatment of cancer | |
AU2002339128A1 (en) | Use of reelin, gas6, and protein s in the treatment of neural disorders | |
AU2002308348A1 (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours | |
CA2387873A1 (en) | Nordihydroguaiaretic derivatives for use in treatment of tumors | |
AU2001283285A1 (en) | Antimicrobial composition and methods of use in the treatment of disease | |
AU2001270484A1 (en) | Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations | |
AU2003286285A1 (en) | Use of fgf-18 in the diagnosis and treatment of memory disorders | |
WO2003099841A9 (en) | Peptides and the use thereof in darkening the skin | |
AU2001265186A1 (en) | Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions | |
IL160018A0 (en) | Isoxazolopyridinones and use thereof in the treatment of parkinson's disease | |
AU2001253886A1 (en) | Methylxanthines in the diagnosis and treatment of autistic disorder | |
AU2002243363A1 (en) | Use of aziridino-compounds in the treatment of immune dysfunctions | |
AU2002352566A1 (en) | Use of corrinoids in the treatment of skin diseases | |
EP1322778A4 (en) | Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas | |
AU2002346049A1 (en) | Coactivators in the diagnosis and treatment of breast cancer | |
AU2002232912A1 (en) | Carbene porphyrins and carbene porphyrinoids for use in medical diagnosis and treatment | |
AU6653698A (en) | Use of the p-ten suppressor gene in diagnosis and treatment of cancer | |
GB0008326D0 (en) | Diagnosis and treatment of autism and related disorders | |
AU2001285026A1 (en) | Methods and compositions for use in the diagnosis and treatment of chronic immune disease |